Abstracts Archive - Page 606 of 2607 - ACR Meeting Abstracts

Abstract Number: 1852 • ACR Convergence 2022
Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study
Silvio Danese¹, Remo Panaccione², David T. Rubin³, Bruce E. Sands⁴, Walter Reinisch⁵, Geert D’Haens⁶, Julián Panés⁷, Susana Gonzalez⁸, Kathleen Weisel⁸, Aparna Sahoo⁸, Mary Ellen Frustaci⁸, Zijiang Yang⁸, William J. Sandborn⁹, Anita Afzali¹⁰, Tadakazu Hisamatsu¹¹, Jane M. Andrews¹² and Brian G. Feagan¹³, ¹Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy, ²Inflammatory Bowel Disease Group, University of Calgary, Calgary, AB, Canada, ³University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, ⁴Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Chicago, IL, ⁵Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria, ⁶Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁷Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA, La Jolla, ¹⁰Wexner Medical Center, The Ohio State University, Columbus, OH, ¹¹Department of Gastroenterology and Hepatology, Kyorin University, Tokyo, Japan, ¹²Department of Gastroenterology & Hepatology, Royal Adelaide Hospital & University of Adelaide, Adelaide, Australia, ¹³Western University and Senior Scientific Director, Alimentiv Inc (formerly Robarts Clinical Trials Inc), London, ON, Canada
Background/Purpose: GALAXI 1 is a Phase 2, double-blind, placebo (PBO)-controlled, multicenter study evaluating the efficacy/safety of guselkumab (GUS), a selective IL-23 p19 antagonist, in patients…
Abstract Number: 1853 • ACR Convergence 2022
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
Mark Yun, Brianne Navetta-Modrov, Hafsa Nomani, Jie Yang and QingPing Yao, Stony Brook University, Stony Brook, NY
Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…
Abstract Number: 1843 • ACR Convergence 2022
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
Vivekanand Tiwari¹, Vishnuteja Devalla², Emily Campbell¹ and William Rigby¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Essential Health St. Joseph's-Brainerd Clinic, Brainerd, MN
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is predominantly based on long-term corticosteroids, which results in significant corticosteroid-related toxicities. Studies1,2 have shown patients with PMR are exposed…
Abstract Number: 1851 • ACR Convergence 2022
Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients
Beibei Zu¹, rongrong wang², Xiaorou Wang³, Bingqing Zhang⁴, Na Xu⁴, Chengjin Huang⁴, Min Shen⁵ and Xuejun Zeng⁴, ¹Department of Rheumatology, Xuzhou Central Hospital, XuZhou, China, ²Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China, ³Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Beijing, China, ⁴Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease, characterized by early‑onset vasculopathy, fever, strokes, livedoid rash, hepatosplenomegaly, and hematologic dysfunction,…
Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…
Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
mingwei tang¹, Qian Wang¹, wei Wei², Pingting Yang³, Xinwang Duan⁴, Hongbin Li⁵, Chanyuan Wu⁶, JIULIANG ZHAO⁷, jia shi¹, Xiaomei Leng⁸, Xinping Tian¹, MENGTAO LI⁹, Yan Zhao¹ and Xiaofeng Zeng¹⁰, ¹Peking Union Medical College Hospital, Beijing, China, ²Tianjin Medical University General Hospital, Tianjin, China, ³The First Hospital of China Medical University, Shenyang, China, ⁴the Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Inner Mongolia Medical University, Hohhot City, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Beijing Union Medical College Hospital, Beijing, China, ⁸Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, ⁹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ¹⁰Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
Abstract Number: 1860 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Nilesh Kodali¹, Thomas Vazquez², DeAnna Diaz³, Josh Dan⁴, Grant Sprow⁵, Rohan Dhiman⁶, Mariko Ogawa-Momohara⁷, Muhammad Bashir⁶, Meena Sharma⁸ and Victoria Werth⁹, ¹New Jersey Medical School, Coppell, TX, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia College of Medicine, Philadelphia, PA, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed…
Abstract Number: 1856 • ACR Convergence 2022
Subclinical Coronary Artery Disease in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Study Evaluation by Computer Tomography Coronary Angiogram
Tsz Ho Luk¹, Weng Nga Lao¹, Steve Pang¹, Ho So², Tak Lung Wong³ and Yan Ki Tang⁴, ¹Kwong Wah Hospital, Hong Kong, Hong Kong, ²Chinese University of Hong Kong, Hong Kong, Hong Kong, ³KWH, Kowloon, Hong Kong, ⁴Kwong Wah Hospital, Hong Kong, China
Background/Purpose: Idiopathic inflammatory myopathy (IIM) poses elevated risk of cardiovascular event and mortality, similar to other autoimmune rheumatic diseases. With the use of computer tomography…
Abstract Number: 1867 • ACR Convergence 2022
YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis
Kazuteru Noguchi¹, Tetsuya Furukawa², Takahiro Yoshikawa¹, Mai Morimoto¹, Teppei Hashimoto², Naoto Azuma³ and Kiyoshi Matsui², ¹Hyogo Medical University, Nishinomiya, Japan, ²Hyogo college of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Background/Purpose: YKL-40 is a chitinase-like protein that is associated with interstitial lung disease in patients with polymyositis (PM)/dermatomyositis (DM) but not with myositis. Myositis pathogenesis…
Abstract Number: 1869 • ACR Convergence 2022
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune…
Abstract Number: 1866 • ACR Convergence 2022
Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
Ehizogie Edigin¹, Amy Trang², Sandhya Shri Kannayiram³, Chinenye Osuorji⁴, Christopher Hino¹, Precious Eseaton⁵, Solomon Anighoro⁶, Augustine Manadan² and Christina Downey⁷, ¹Loma Linda University Health, Loma Linda, CA, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ⁴Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, ⁵University of South Wales, Cardiff, Wales, United Kingdom, ⁶St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, ⁷Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Polymyositis (PM)/ Dermatomyositis (DM) is a chronic immune-mediated myositis characterized by relapses that can lead to frequent hospitalizations. There is a scarcity of national…
Abstract Number: 1868 • ACR Convergence 2022
B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1810 • ACR Convergence 2022
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
Tuhina Neogi¹, Martin Englund², Aleksandra Turkiewicz² and Ali Kiadaliri², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Treatment guidelines for management of gout do not recommend opioids. We evaluated the frequency of opioid prescriptions in those with gout compared with the…
Abstract Number: 1759 • ACR Convergence 2022
Factors Affecting Success of Behavioral Interventions to Improve Physical Activity in Patients with Knee Osteoarthritis
Lakshmi Jayaram¹, jing song², Pamela Semanik³, Daniel Pinto⁴, Linda Ehrlich-Jones⁵, Lutfiyya Muhammad⁶, Alison Chang⁶ and Rowland Chang⁷, ¹McGaw Medical Center, Northwestern University, Chicago, IL, ²Northwestern University, Chicago, IL, ³Rush University, Chicago, IL, ⁴Marquette University, Wauwatosa, WI, ⁵Shirley Ryan AbilityLab, Aurora, IL, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Knee osteoarthritis (KOA) is a chronic long-term condition that results in pain, disability and reduced quality of life. Over 13 million US adults 45…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].